The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study

• Hauptverfasser: Yusi Chen (Verfasst von), Jun Luo (Verfasst von), Jingyuan Chen (Verfasst von), Eugene Kotlyar (Verfasst von), Zilu Li (Verfasst von), Wenjie Chen (Verfasst von), Jiang Li (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Background: In a long-term event-driven trial, macitentan has demonstrated beneficial time to clinical worsening in patients with pulmonary arterial hypertension (PAH) and reduced PAH-related hospitalization rates compared with placebo. Macitentan is the most recently approved endothelin receptor an...